Thurston Springer Miller Herd & Titak Inc. Has $308,000 Stock Holdings in DaVita Inc. (NYSE:DVA)

Thurston Springer Miller Herd & Titak Inc. raised its position in DaVita Inc. (NYSE:DVA) by 23.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,015 shares of the company’s stock after buying an additional 385 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in DaVita were worth $308,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Copia Wealth Management acquired a new stake in shares of DaVita during the 4th quarter worth $30,000. SBI Securities Co. Ltd. acquired a new stake in shares of DaVita during the 4th quarter worth $41,000. Coppell Advisory Solutions LLC grew its holdings in shares of DaVita by 50.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock worth $45,000 after purchasing an additional 100 shares in the last quarter. Canada Post Corp Registered Pension Plan acquired a new stake in shares of DaVita during the 4th quarter worth $55,000. Finally, Venturi Wealth Management LLC lifted its position in shares of DaVita by 59.8% during the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock worth $61,000 after buying an additional 152 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Price Performance

DaVita stock opened at $137.95 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The company has a market capitalization of $10.41 billion, a PE ratio of 12.84, a P/E/G ratio of 1.07 and a beta of 1.11. DaVita Inc. has a 12 month low of $131.76 and a 12 month high of $179.60. The stock has a 50-day moving average price of $142.56 and a two-hundred day moving average price of $152.14.

DaVita (NYSE:DVA) last posted its earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating the consensus estimate of $1.75 by $0.25. The firm had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The business’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the company earned $2.26 earnings per share. Analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Barclays upped their price objective on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Truist Financial dropped their price objective on DaVita from $170.00 to $164.00 and set a “hold” rating for the company in a research report on Monday, May 19th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research report on Friday, February 21st. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Friday, April 25th. Finally, Cowen restated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, DaVita presently has a consensus rating of “Hold” and a consensus target price of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.